Revolution Medicines, Inc.
RVMD
주식 순위
#579
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
주가
$196.16
시가총액
$42.04B
변동 (1일)
7.69%
변동 (1년)
263.19%
국가
US
거래 Revolution Medicines, Inc. (RVMD)
카테고리
Healthcare
Revolution Medicines, Inc. (RVMD)의 발행 주식 수
June 2026 기준 발행 주식 수: 210.89M
Revolution Medicines, Inc.의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 210.89M입니다. December 2023 말 기준 회사는 113.15M주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Revolution Medicines, Inc. (RVMD)의 발행 주식 수 기록 (2017 ~ 2026)
매년 말 기준 발행 주식 수
| 연도 | 발행 주식 수 | 변화 |
|---|---|---|
| 2026 (TTM) | 210.89M | 25.73% |
| 2024 | 167.74M | 48.24% |
| 2023 | 113.15M | 40.34% |
| 2022 | 80.63M | 10.74% |
| 2021 | 72.81M | 9.32% |
| 2020 | 66.60M | 82.60% |
| 2019 | 36.47M | 0.00% |
| 2018 | 36.47M | 0.00% |
| 2017 | 36.47M | 0.00% |
유사 기업 또는 경쟁사의 발행 주식 수
| 회사 | 발행 주식 수 | 차이 | 국가 |
|---|---|---|---|
| 253.90M | 20.39% |
US
|
|
| 396.00M | 87.77% |
US
|
|
| 478.91M | 127.09% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -70.51% |
NL
|
